Related Experiment Video
Updated: Sep 25, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD
Nina Friis-Møller1, Rainer Weber, Peter Reiss
1DAD Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark. nfm@cphiv.dk
Insights
HIV-infected individuals have numerous cardiovascular disease risk factors. Certain antiretroviral therapies, particularly protease inhibitors and non-nucleoside reverse transcriptase inhibitors, are linked to higher cholesterol levels, increasing heart disease risk.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Cardiovascular disease (CVD) is a significant concern in HIV-infected populations.
- Understanding CVD risk factors in this demographic is crucial for effective management.
Purpose of the Study:
- To determine the prevalence of CVD risk factors in HIV-infected individuals.
- To investigate associations between these risk factors, HIV disease stage, and antiretroviral therapy (ART) use.
Main Methods:
- Analysis of baseline data from 17,852 subjects in the DAD prospective multinational cohort study.
- Cross-sectional assessment of demographic variables, smoking, diabetes, hypertension, dyslipidemia, BMI, HIV stage, and ART use.
Main Results:
- Over 25% of the population were in an age group with appreciable CVD risk.
- Elevated total cholesterol was significantly associated with protease inhibitor (PI) and/or non-nucleoside reverse transcriptase inhibitor (NNRTI) use compared to ART-naive subjects.
- Higher CD4 cell count, lower HIV RNA, lipodystrophy, longer PI/NNRTI exposure, and older age were linked to elevated cholesterol.
Conclusions:
- HIV-infected individuals present with multiple CVD risk factors.
- Use of NNRTI and PI drug classes, especially in combination, is associated with adverse lipid profiles, increasing coronary heart disease risk, particularly in older individuals with controlled HIV.
Objective:
To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies.
Design:
Baseline data from 17,852 subjects enrolled in DAD, a prospective multinational cohort study initiated in 1999.
Methods:
Cross-sectional analyses of CVD risk factors at baseline. The data collected includes data on demographic variables, cigarette smoking, diabetes mellitus, hypertension, dyslipidaemia, body mass index, stage of HIV infection, antiretroviral therapy.
Results:
Almost 25% of the study population were at an age where there is an appreciable risk of CVD, with those receiving a protease inhibitor (PI) and/or non-nucleoside reverse transcriptase inhibitor (NNRTI) tending to be older. 1.4% had a previous history of CVD and 51.5% were cigarette smokers. Increased prevalence of elevated total cholesterol (> or = 6.2 mmol/l) was observed among subjects receiving an NNRTI but no PI [odds ratio (OR), 1.79; 95% confidence interval (CI), 1.45-2.22], PI but no NNRTI (OR, 2.35; 95% CI, 1.92-2.87), or NNRTI + PI (OR, 5.48; 95% CI, 4.34-6.91) compared to the prevalence among antiretroviral therapy (ART)-naive subjects. Subjects who have discontinued ART as well as subjects receiving nucleoside reverse transcriptase inhibitors had similar cholesterol levels to treatment-naive subjects. Higher CD4 cell count, lower plasma HIV RNA levels, clinical signs of lipodystrophy, longer exposure times to NNRTI and PI, and older age were all also associated with elevated total cholesterol level.
Conclusion:
HIV-infected persons exhibit multiple known risk factors for CVD. Of specific concern is the fact that use of the NNRTI and PI drug classes (alone and especially in combination), particularly among older subjects with normalized CD4 cell counts and suppressed HIV replication, was associated with a lipid profile known to increase the risk of coronary heart disease.
Related Concept Videos
Retrovirus Life Cycles
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures
Amebiasis
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

